006280 — GC Biopharma Share Price
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩3tn
- KR₩2tn
- 23
- 38
- 65
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 43.27 | ||
| PEG Ratio (f) | 0.48 | ||
| EPS Growth (f) | 851.81% | ||
| Dividend Yield (f) | 1.13% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.24 | ||
| Price to Tang. Book | 1.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.98 | ||
| EV to EBITDA | 23.61 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.69% | ||
| Return on Equity | -1.45% | ||
| Operating Margin | 2.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 1,357,117.27 | 1,504,115.28 | 1,537,825.75 | 1,711,312.74 | 1,626,643.82 | 1,719,128 | 1,855,443 | 4.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -82.71 | +455.46 | +210.24 | -72.35 | n/a | n/a | +600.39 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Green Cross Corp is a Korea-based company that mainly engaged in the manufacture and sale of pharmaceutical products. The Company mainly manufactures pharmaceutical products including blood products, general products, vaccines, over the counter (OTC) drugs, diagnostic reagents, placental injections, cell therapies, vaccine fertilized eggs and blood diagnostic products, among others. The Company also provides genome analysis services.
Directors
- Eun Cheol Huh CEO (44)
- Yeong Ho Kim VPR (57)
- Yeong Chan Lee VPR (56)
- Su Hyeon Jung MDR (56)
- Yeong Pil Kim MDR (54)
- Chang Hui Lee MDR (49)
- Bok Su Park MDR (57)
- Dae Wu Park MDR (58)
- Du Hong Park MDR (56)
- Sang Hun Cho OTH (58)
- Ji Hun Han OTH (58)
- Pyeong Ju Jang OTH (50)
- Mun Ho Jung OTH (54)
- Byeong Hwa Kim OTH (52)
- Gyeong Jo Kim OTH (54)
- Seon Wuk Lee OTH (48)
- Yin Jae Lee OTH (50)
- Jong Ho Noh OTH (53)
- Myeong Jae Lee NID (72)
- Seong Tae Yoon NID (70)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- November 1st, 1969
- Public Since
- August 1st, 1989
- No. of Shareholders
- 60,799
- No. of Employees
- 1,766
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 11,413,178
- Address
- 107, Ihyeon-ro 30beon-gil, Giheung-gu, YONGIN, 16924
- Web
- http://gcbiopharma.com/
- Phone
- +82 312609300
- Auditors
- Ernst & Young Han Young
Upcoming Events for 006280
GC Biopharma Corp Annual Shareholders Meeting
Q1 2025 GC Biopharma Corp Earnings Release
Similar to 006280
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the GC Biopharma share price?
As of Today at 19:57 UTC, shares in GC Biopharma are trading at KR₩140,600. This share price information is delayed by 15 minutes.
How has the GC Biopharma share price performed this year?
Shares in GC Biopharma last closed at KR₩140,600 and the price had moved by +15.66% over the past 365 days. In terms of relative price strength the GC Biopharma share price has outperformed the FTSE Developed Asia Pacific Index by +9.9% over the past year.
What are the analyst and broker recommendations for GC Biopharma?
The overall consensus recommendation for GC Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the GC Biopharma dividend yield?
The GC Biopharma dividend yield is 1.07% based on the trailing twelve month period.
Does GC Biopharma pay a dividend?
Last year, GC Biopharma paid a total dividend of KR₩1,500, and it currently has a trailing dividend yield of 1.07%. We do not have any data on when GC Biopharma is to next pay dividends.
When does GC Biopharma next pay dividends?
We do not have data on when GC Biopharma is to next pay dividends. The historic dividend yield on GC Biopharma shares is currently 1.07%.
How do I buy GC Biopharma shares?
To buy shares in GC Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of GC Biopharma?
As of the previous close price of KR₩140,600, shares in GC Biopharma had a market capitalisation of KR₩2tn.
Where are GC Biopharma shares listed?
Here are the trading details for GC Biopharma:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 006280
What kind of share is GC Biopharma?
Based on an overall assessment of its quality, value and momentum GC Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a GC Biopharma share price forecast for 2024?
The analyst consensus target price for shares in GC Biopharma is KR₩193,167. That is 37.39% above the last closing price of KR₩140,600.
Analysts covering GC Biopharma currently have a consensus Earnings Per Share (EPS) forecast of KR₩487 for the next financial year.
Find out moreWhat is the trend in the GC Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GC Biopharma. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +19.94%.
As of the last closing price of KR₩140,600, shares in GC Biopharma were trading +5.29% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the GC Biopharma PE Ratio?
The GC Biopharma PE ratio based on its reported earnings over the past 12 months is 43.27. The shares last closed at KR₩140,600.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of GC Biopharma?
GC Biopharma's management team is headed by:
- Eun Cheol Huh - CEO
- Yeong Ho Kim - VPR
- Yeong Chan Lee - VPR
- Su Hyeon Jung - MDR
- Yeong Pil Kim - MDR
- Chang Hui Lee - MDR
- Bok Su Park - MDR
- Dae Wu Park - MDR
- Du Hong Park - MDR
- Sang Hun Cho - OTH
- Ji Hun Han - OTH
- Pyeong Ju Jang - OTH
- Mun Ho Jung - OTH
- Byeong Hwa Kim - OTH
- Gyeong Jo Kim - OTH
- Seon Wuk Lee - OTH
- Yin Jae Lee - OTH
- Jong Ho Noh - OTH
- Myeong Jae Lee - NID
- Seong Tae Yoon - NID